(Rivas et al., 2011), autism (Sanders et al., 2012), schizophrenia (Girard et al., 2011), impulsivity (Bevilacqua et al., 2010), and nicotine dependence (Xie et al., 2011). Next-generation high throughput sequencing technologies have recently rendered deep sequencing projects more feasible. However, whole-exome or whole-genome sequencing a large number of patients are still costly. We therefore focused on genes involved in the glutamatergic pathway and investigated the RV contribution to substance dependence (SD) risk, using deep high throughput sequencing.
